Prognostic Factors on the Graft-versus-Host Disease-Free and Relapse-Free Survival after Adult Allogeneic Hematopoietic Stem Cell Transplantation

Table 2

Prognostic factors for 1-year GRFS after adult allogeneic HSCT.

Factors		Events	%	Univariate analysis			Multivariate analysis
				HR	95% CI	value	HR	95% CI	value
Age at HSCT
35	139	69	49.6	1.446	1.087–1.923	0.011	1.068	0.783–1.456	0.679
35	238	151	63.4
EBMT risk score
2	155	67	43.2	2.197	1.647–2.913	<0.001	1.897	1.385–2.599	<0.001
2	222	153	68.9
Gender
Female	168	84	50.0	1.419	1.081–1.863	0.012	1.310	0.994–1.725	0.055
Male	209	136	65.1
Disease type
Nonmalignant	48	16	33.3	2.244	1.348–3.735	0.002	1.763	1.048–2.966	0.033
Malignant	329	204	62.0
Disease type
Myeloid	176	111	63.1	0.835	0.641–1.088	0.182
Nonmyeloid	201	109	54.2
Conditioning
Nonmyeloablative	129	72	55.8	1.084	0.818–1.436	0.576
Myeloablative	248	148	59.7
Conditioning
Others	252	142	56.3	1.212	0.920–1.598	0.172
12 Gy TBI based	125	78	62.4
Conditioning
Others	303	168	55.4	1.491	1.092–2.036	0.012	1.134	0.818–1.574	0.450
Fludarabine based	74	52	70.2
Donor type
Matched sibling	181	111	61.3	1.005	0.771–1.309	0.971
Others	196	109	55.6
Type 2 DM
No	362	210	58.0	1.339	0.710–2.526	0.367
Yes	15	10	66.7
Smoking history
No	353	204	57.8	1.348	0.810–2.242	0.250
Yes	24	16	66.7
Posttransplant CMV reactivation
No	189	101	53.4	1.335	1.024–1.741	0.033	1.160	0.884–1.522	0.285
Yes	188	119	63.3
PTLD
No	363	212	58.4	1.047	0.517–2.120	0.899
Yes	14	8	57.1

CI: confidence interval; HR: hazard ratio; EBMT: European Group for Blood and Marrow Transplantation; HSCT: hematopoietic stem cell transplantation; PTLD: posttransplant lymphoproliferative disorders; DM: diabetes mellitus; CMV: cytomegalovirus; TBI: total body irradiation.
Factors with statistical significance () upon univariate analysis were included in multivariate analysis.